
NATCO Pharma Ltd. share price
NSE: NATCOPHARM · Healthcare
₹828.65 +2.25%
Closing price data, updated 17 Nov 2026. 52-week range: -32.5% from high, +7.1% above low.
Price₹828.65
Market cap₹14,963 Cr
P/E13.1
P/B1.62
ROE16.9%
ROCE16.1%
Debt / equity0.08
Dividend yield0.00%
EPS₹63.37
Book value₹510.67
Operating margin31.1%
Dipscan score63 / 100
Share: WhatsAppX / TwitterTelegram
NATCO Pharma Ltd. shareholding pattern
As of Sep 2026: Promoters 49.39%, FIIs 16.00%, DIIs 6.16%, Government 0.00%, Public 23.85%, Others 4.60%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 49.39% | 49.42% | 49.42% | 49.48% | 49.48% | 49.56% |
| FIIs | 16.00% | 16.99% | 17.37% | 15.16% | 14.09% | 15.51% |
| DIIs | 6.16% | 5.62% | 5.46% | 5.39% | 5.87% | 5.82% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 23.85% | 23.41% | 23.34% | 25.38% | 25.84% | 25.22% |
| Others | 4.60% | 4.56% | 4.41% | 4.58% | 4.72% | 3.89% |
| No. of Shareholders | 404,135 | 403,166 | 410,970 | 424,167 | 419,699 | 429,434 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| +2.25% | +2.68% | +5.88% | -12.93% | -31.20% | +4.50% |
Growth
| Sales growth, 3 years | +14.5% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +25.6% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | -44.7% |
| Latest quarter profit vs last year | -57.0% |
Strengths and weaknesses
Strengths
- Company has delivered good profit growth of 28.1% CAGR over last 5 years
Weaknesses
- Promoter holding has decreased over last quarter: -3.19%
- Tax rate seems low
- Earnings include an other income of Rs.247 Cr.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of NATCO Pharma Ltd.?
NATCO Pharma Ltd. (NATCOPHARM) last closed at ₹828.65 (+2.25% on the day).
What is the market cap of NATCO Pharma Ltd.?
About ₹14,963 Cr.
What is the P/E ratio of NATCO Pharma Ltd.?
The price-to-earnings ratio is 13.1, and return on equity is 16.9%.
Figures are calculated from company results and exchange prices and are for information only.